Which has higher valuation and earnings, ARTV or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Artiva Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics $250K 1,106.37 -$83.86M -$3.30 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is ARTV or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -83.31% -70.63% OKYO Pharma N/A N/A N/A

Which has preferable earnings & valuation, ALXO or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.13 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is ALXO or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% OKYO Pharma N/A N/A N/A

Which has higher valuation & earnings, OKYO or ANIK?

OKYO Pharma has higher earnings, but lower revenue than Anika Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Anika Therapeutics $120.65M 2.30 -$10.88M -$0.27 N/A

Which has higher valuation and earnings, SRZN or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Surrozen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 83.85 -$242.03M -$40.55 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is SRZN or OKYO more profitable?

OKYO Pharma has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Surrozen -2,885.33% N/A -96.11% OKYO Pharma N/A N/A N/A

Which has preferable earnings & valuation, MGNX or OKYO?

OKYO Pharma has lower revenue, but higher earnings than MacroGenics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $157.08M 1.63 -$74.62M -$1.10 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is MGNX or OKYO more profitable?

OKYO Pharma has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. OKYO Pharma's return on equity of 0.00% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% OKYO Pharma N/A N/A N/A

OKYO Pharma (OKYO) Competitors

$1.58 +0.09 (+6.04%)

As of 02:09 PM Eastern

Compare

OKYO vs. ARTV, ALXO, ANIK, SRZN, and MGNX

Should you buy OKYO Pharma stock or one of its competitors? MarketBeat compares OKYO Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OKYO Pharma include Artiva Biotherapeutics (ARTV), ALX Oncology (ALXO), Anika Therapeutics (ANIK), Surrozen (SRZN), and MacroGenics (MGNX). These companies are all part of the "biotechnology" industry.

How does OKYO Pharma compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than OKYO Pharma. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 0 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.00 beat Artiva Biotherapeutics' score of -0.57 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Artiva Biotherapeutics	Negative
OKYO Pharma	Neutral

OKYO Pharma has lower revenue, but higher earnings than Artiva Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,106.37	-$83.86M	-$3.30	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Artiva Biotherapeutics has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

3.0% of OKYO Pharma shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

OKYO Pharma's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-83.31%	-70.63%
OKYO Pharma	N/A	N/A	N/A

Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 248.56%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 258.65%. Given OKYO Pharma's higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

OKYO Pharma beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does OKYO Pharma compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

ALX Oncology currently has a consensus target price of $4.60, suggesting a potential upside of 123.84%. OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 258.65%. Given OKYO Pharma's higher probable upside, analysts clearly believe OKYO Pharma is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

OKYO Pharma's return on equity of 0.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
OKYO Pharma	N/A	N/A	N/A

In the previous week, ALX Oncology had 4 more articles in the media than OKYO Pharma. MarketBeat recorded 4 mentions for ALX Oncology and 0 mentions for OKYO Pharma. ALX Oncology's average media sentiment score of 0.71 beat OKYO Pharma's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
ALX Oncology	Positive
OKYO Pharma	Neutral

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 12.4% of ALX Oncology shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ALX Oncology has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Summary

ALX Oncology beats OKYO Pharma on 6 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to Anika Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

OKYO Pharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

OKYO Pharma has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat OKYO Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Anika Therapeutics	-3.14%	0.20%	0.15%

In the previous week, Anika Therapeutics had 6 more articles in the media than OKYO Pharma. MarketBeat recorded 6 mentions for Anika Therapeutics and 0 mentions for OKYO Pharma. Anika Therapeutics' average media sentiment score of 1.11 beat OKYO Pharma's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Anika Therapeutics	Positive

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OKYO Pharma has higher earnings, but lower revenue than Anika Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Anika Therapeutics	$120.65M	2.30	-$10.88M	-$0.27	N/A

OKYO Pharma currently has a consensus target price of $5.67, indicating a potential upside of 258.65%. Anika Therapeutics has a consensus target price of $21.00, indicating a potential upside of 1.23%. Given OKYO Pharma's higher probable upside, research analysts plainly believe OKYO Pharma is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Anika Therapeutics beats OKYO Pharma on 9 of the 14 factors compared between the two stocks.

How does OKYO Pharma compare to Surrozen?

Surrozen (NASDAQ:SRZN) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Surrozen has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

OKYO Pharma has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-96.11%
OKYO Pharma	N/A	N/A	N/A

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 67.10%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 258.65%. Given OKYO Pharma's higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Surrozen had 5 more articles in the media than OKYO Pharma. MarketBeat recorded 5 mentions for Surrozen and 0 mentions for OKYO Pharma. Surrozen's average media sentiment score of 1.24 beat OKYO Pharma's score of 0.00 indicating that Surrozen is being referred to more favorably in the media.

Company	Overall Sentiment
Surrozen	Positive
OKYO Pharma	Neutral

OKYO Pharma has lower revenue, but higher earnings than Surrozen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	83.85	-$242.03M	-$40.55	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Summary

Surrozen beats OKYO Pharma on 7 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MacroGenics presently has a consensus target price of $5.50, suggesting a potential upside of 36.65%. OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 258.65%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

OKYO Pharma has lower revenue, but higher earnings than MacroGenics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$157.08M	1.63	-$74.62M	-$1.10	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

OKYO Pharma has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. OKYO Pharma's return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
OKYO Pharma	N/A	N/A	N/A

In the previous week, MacroGenics had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for MacroGenics and 0 mentions for OKYO Pharma. MacroGenics' average media sentiment score of 0.34 beat OKYO Pharma's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Neutral
OKYO Pharma	Neutral

Summary

OKYO Pharma beats MacroGenics on 7 of the 12 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.09M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.08	269.95	24.78
Price / Sales	N/A	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	5.27	17.64	11.25	6.43
Net Income	-$8.95M	-$13.25M	$3.45B	$347.27M
7 Day Performance	-5.39%	5.21%	3.49%	2.53%
1 Month Performance	-6.51%	-1.94%	-0.66%	-1.03%
1 Year Performance	-51.68%	60.76%	77.20%	23.28%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	1.7911 of 5 stars	$1.58 +6.0%	$5.67 +258.6%	-54.4%	$64.09M	N/A	N/A	7	Gap Up
ARTV Artiva Biotherapeutics	2.7705 of 5 stars	$10.82 -2.3%	$39.00 +260.4%	+308.3%	$267.47M	$250K	N/A	81	Earnings Report Analyst Upgrade
ALXO ALX Oncology	2.2753 of 5 stars	$1.94 -1.5%	$4.60 +137.1%	+210.3%	$261.05M	N/A	N/A	40	Earnings Report
ANIK Anika Therapeutics	3.4535 of 5 stars	$19.32 -1.5%	$21.00 +8.7%	+164.1%	$258.50M	$112.82M	N/A	300	Positive News Gap Up
SRZN Surrozen	3.041 of 5 stars	$21.53 -2.1%	$42.00 +95.1%	+168.0%	$249.96M	$3.48M	N/A	80	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. ARTV, ALXO, ANIK, SRZN, and MGNX

How does OKYO Pharma compare to Artiva Biotherapeutics?

Summary

How does OKYO Pharma compare to ALX Oncology?

Summary

How does OKYO Pharma compare to Anika Therapeutics?

Summary

How does OKYO Pharma compare to Surrozen?

Summary

How does OKYO Pharma compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. ARTV, ALXO, ANIK, SRZN, and MGNX

How does OKYO Pharma compare to Artiva Biotherapeutics?

Does the media refer more to ARTV or OKYO?

Which has higher valuation and earnings, ARTV or OKYO?

Which has more volatility and risk, ARTV or OKYO?

Do institutionals & insiders have more ownership in ARTV or OKYO?

Is ARTV or OKYO more profitable?

Do analysts rate ARTV or OKYO?

Summary

How does OKYO Pharma compare to ALX Oncology?

Which has preferable earnings & valuation, ALXO or OKYO?

Do analysts rate ALXO or OKYO?

Is ALXO or OKYO more profitable?

Does the media refer more to ALXO or OKYO?

Do insiders & institutionals have more ownership in ALXO or OKYO?

Which has more volatility & risk, ALXO or OKYO?

Summary

How does OKYO Pharma compare to Anika Therapeutics?

Which has more risk and volatility, OKYO or ANIK?

Is OKYO or ANIK more profitable?

Does the media favor OKYO or ANIK?

Do insiders and institutionals have more ownership in OKYO or ANIK?

Which has higher valuation & earnings, OKYO or ANIK?

Do analysts rate OKYO or ANIK?

Summary

How does OKYO Pharma compare to Surrozen?

Which has more risk & volatility, SRZN or OKYO?

Do institutionals & insiders have more ownership in SRZN or OKYO?

Is SRZN or OKYO more profitable?

Do analysts prefer SRZN or OKYO?

Does the media prefer SRZN or OKYO?

Which has higher valuation and earnings, SRZN or OKYO?

Summary

How does OKYO Pharma compare to MacroGenics?

Do insiders & institutionals have more ownership in MGNX or OKYO?

Do analysts prefer MGNX or OKYO?

Which has preferable earnings & valuation, MGNX or OKYO?

Which has more risk and volatility, MGNX or OKYO?

Is MGNX or OKYO more profitable?

Does the media prefer MGNX or OKYO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools